Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Brigham and Women's Hospital | OTHER |
| University of Michigan | OTHER |
| VA Loma Linda Health Care System | FED |
| Kaiser Foundation Research Institute |
Not provided
Not provided
Not provided
Not provided
In the US, patients receiving warfarin therapy are rarely allowed to engage in patient self-management (PSM) which is less burdensome, less expensive, and safer than standard clinic-directed warfarin management. The long-term objective of our application is to improve the safety of ambulatory warfarin therapy through increasing the implementation of PSM.
In the US, patients receiving warfarin therapy are rarely allowed to engage in patient self-management (PSM) which is less burdensome, less expensive, and safer than standard clinician-directed warfarin management. National and international evidence-based guideline panels strongly recommend PSM over other warfarin management methods for appropriate patients because it improves INR control, cuts risk of thrombosis and death by half without increasing bleeding risk, and increases patient satisfaction and quality of life. The reasons behind PSM underutilization in US settings have not been systematically assessed and validated. We will address this knowledge gap and provide foundational information for increasing PSM utilization within the US healthcare system. Our Aim 1 will assess and validate barriers and facilitators to PSM and evaluate their applicability to the US healthcare system; Aim 2 will develop and test PSM implementation strategies in US ambulatory care sites using rapid-cycle research methodology; and Aim 3 will assess implementation (feasibility, fidelity, adoption), clinical (effectiveness, safety, equity, patient-centeredness), and end-user (satisfaction) outcomes. The long-term objective of our application is to improve the safety of ambulatory warfarin therapy through increasing the implementation of PSM. Our research proposal is guided by an implementation science logic model that incorporates well-known implementation science frameworks to support the specific aims. Qualitative data collection and analysis for Aim 1 will be organized using the Consolidated Framework for Implementation Research (CFIR) a determinant framework that identifies five domains influencing implementation: Intervention, Inner Setting, Outer Setting, Individuals, and the Implementation Process. Constructs within each domain provide guidance on factors to identify and measure as potential implementation barriers or facilitators. PSM implementation activities in Aim 2 will be guided by the Quality Implementation Framework (QIF), which identifies the critical implementation process steps and specific actions related to these steps that can be utilized to achieve quality PSM implementation. Implementation strategies will be supported by the rapid-cycle research framework developed by the AHRQ Practice Based Research Network. Implementation outcomes in Aim 3 will be structured using the well-known Reach, Efficacy, Adoption, Implementation, Maintenance (RE-AIM) framework. We will utilize a type III hybrid research design to test PSM implementation strategies while observing/gathering information on PSM-related clinical and economic outcomes.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Warfarin Patient Self-Management | Experimental | Patients managing decisions relating to warfarin dose and next INR test based on the results of current INR test |
|
| Historical Control | Active Comparator | Patients managed by anticoagulation providers prior to transitioning to warfarin patient self-management |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patient self-management | Other | Patient makes independent decisions regarding warfarin therapy changes using warfarin dosing tools |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time in therapeutic INR range (TTR) | Percent time INR in the therapeutic range | Change from baseline at 6 months |
| Percent of patients transitioned to patient self-management | Percent of patients successfully transitioned to warfarin patient self-management | 6-months follow up |
| Measure | Description | Time Frame |
|---|---|---|
| Episodes of major bleeding | Episodes of bleeding meeting ISTH definition for major bleeding | 6-months follow up |
| Episodes of thromboembolic complications | Objectively diagnosed stroke, venous thrombosis, systemic embolism |
| Measure | Description | Time Frame |
|---|---|---|
| Patient self-management cost effectiveness | Cohort simulation Markov model compared to usual care | 3-month cycles |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Daniel M Witt, PharmD | Contact | 801-581-8851 | dan.witt@pharm.utah.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VA Loma Linda Healthcare System | Recruiting | Loma Linda | California | 92357 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41854610 | Derived | Witt DM, Hong H, Wilson AS, Jones AE, Vazquez SR, Gilbert SJ, Malone DC, Chaiyakunapruk N, King JB, Barnes GD, Sylvester KW, Chan L, Delate T. Warfarin Patient Self-Management in the US Health Care System: A Nonrandomized Clinical Trial. JAMA Netw Open. 2026 Mar 2;9(3):e262627. doi: 10.1001/jamanetworkopen.2026.2627. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Mar 12, 2026 | |
| Reset | Apr 1, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 12, 2026 | Apr 1, 2026 |
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| D054556 | Venous Thromboembolism |
| D006349 | Heart Valve Diseases |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| Usual care provided by anticoagulation providers | Other | Normal care provided by anticoagulation providers |
|
| 6-months follow |
| Mental and physical health-related quality of life scores | Mental and physical domains of quality of life as measured by the SF-12 survey | Change from baseline at 6 months |
| Anticoagulation therapy knowledge scores | Scores measured by the Anticoagulation Knowledge Survey Tool | Change from baseline at 6 months |
| Patient satisfaction survey scores | Patient satisfaction as measured by the Anti-Clot Treatment Scale | Change from baseline at 6 months |
| Brigham and Women's Hospital | Completed | Boston | Massachusetts | 02115 | United States |
| University of Michigan | Completed | Ann Arbor | Michigan | 48109 | United States |
| University of Utah Thrombosis Center | Recruiting | Salt Lake City | Utah | 84112 | United States |
|
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |